GW Pharma’s Epidyolex scores new EU indication
Cannabis-based medicine approved for the treatment of seizures associated with tuberous sclerosis complex
Read More
Tag: Tuberous Sclerosis Complex
GW Pharmaceuticals announce quarterly financial results
GW Pharmaceuticals has reported revenue growth of 67.5% for the fourth quarter, driven by demand for Epidiolex.
Read More
- MRM Health collaborates with Oncode Institute and Netherlands Cancer Institute
- Sobi to acquire Arthrosi Therapeutics, strengthening gout treatment pipeline
- Lindus Health and Quotient Sciences announce strategic partnership to accelerate drug development
- Title21 Health Solutions joins the Blood and Cells Advocacy Roster
- NADMED launches $30,000 metabolomics research award
